Analysis of the drug therapy of gatifloxacin and levofloxacin in the treatment of acute bacterial conjunctivitis
- PMID: 30203775
Analysis of the drug therapy of gatifloxacin and levofloxacin in the treatment of acute bacterial conjunctivitis
Abstract
Acute bacterial conjunctivitis is an acute conjunctivitis that is frequently transmitted in summer and autumn. It is a common and frequently occurring disease in ophthalmology clinic. Gatifloxacin is an effective antibacterial drug. It not only maintains the antibacterial effect of the three generation of fluoroquinolones on Gram-negative bacteria, but also enhances the effectiveness of gatifloxacin, including other Gram-positive bacteria and anaerobes. In this paper, by taking gatifloxacin eye drops as the experimental drug and levofloxacin as the control drug, we conducted a double-blind randomized controlled clinical trial to evaluate the efficacy and safety of gatifloxacin eye drops in the treatment of acute bacterial conjunctivitis. The clinical results showed that the total effective rate of the Gatifloxacin treatment group was 95%. Conclusion shows that gatifloxacin is a safe and effective antibiotic eye drops. It has broad antibacterial spectrum, strong antibacterial activity and effective clinical treatment, and it can effectively treat acute bacterial conjunctivitis.
Similar articles
-
[Comparative research of the efficacy of the gatifloxacin and levofloxacin for bacterial conjunctivitis in human eyes].Zhonghua Yan Ke Za Zhi. 2010 Jun;46(6):525-31. Zhonghua Yan Ke Za Zhi. 2010. PMID: 21055198 Clinical Trial. Chinese.
-
Effect of gatifloxacin in the treatment of ophthalmological diseases and continuous nursing intervention.Pak J Pharm Sci. 2018 Jul;31(4(Special)):1707-1712. Pak J Pharm Sci. 2018. PMID: 30203767 Clinical Trial.
-
Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.J Ocul Pharmacol Ther. 2018 Apr;34(3):250-255. doi: 10.1089/jop.2017.0056. Epub 2018 Jan 11. J Ocul Pharmacol Ther. 2018. PMID: 29624493 Clinical Trial.
-
Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.Adv Ther. 2008 Oct;25(10):979-94. doi: 10.1007/s12325-008-0107-x. Adv Ther. 2008. PMID: 18836691 Review.
-
The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.Drugs. 2019 Feb;79(2):161-171. doi: 10.1007/s40265-018-1043-y. Drugs. 2019. PMID: 30617959 Free PMC article. Review.
Cited by
-
Synergistic effect of chlorogenic acid and levofloxacin against Klebsiella pneumonia infection in vitro and in vivo.Sci Rep. 2020 Nov 17;10(1):20013. doi: 10.1038/s41598-020-76895-5. Sci Rep. 2020. PMID: 33203903 Free PMC article.